Ta strona używa pliki cookies, w celu polepszenia użyteczności i funkcjonalności oraz w celach statystycznych. Dowiedz się więcej w Polityce prywatności.
Korzystając ze strony wyrażasz zgodę na używanie plików cookies, zgodnie z aktualnymi ustawieniami przeglądarki.
Akceptuję wykorzystanie plików cookies
eISSN: 2449-8238
ISSN: 2392-1099
Clinical and Experimental Hepatology
Current issue Archive Manuscripts accepted About the journal Editorial board Subscription Contact Instructions for authors Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
4/2024
vol. 10
 
Share:
Share:
abstract:
Review paper

Cannabinoids and the endocannabinoid system in liver diseases

Anna Parfieniuk-Kowerda
1
,
Diana Martonik
1
,
Aleksandra Andrzejuk
2
,
Aleksander Tarasik
3
,
Robert Flisiak
1

  1. Department of Infectious Diseases and Hepatology, Medical University of Bialystok, Białystok, Poland
  2. Faculty of Medicine, Medical University of Białystok, Białystok, Poland
  3. Colorectal Cancer Unit, Maria Sklodowska-Curie Bialystok Oncology Centre, Białystok, Poland
Clin Exp HEPATOL 2024; 10, 4: 211-217
Online publish date: 2024/12/12
View full text Get citation
 
PlumX metrics:
Cannabinoids are biologically active substances acting via feedback-coupled CB1 and CB2 receptors. Their expression in myofibroblasts and liver endothelial cells is reported to be elevated in chronic liver diseases. The effect of CB1 receptor stimulation is to increase fibrosis and inflammatory activity in the liver by stimulating stellate cells, while activation of the CB2 receptor results in inhibition of fibrosis. Stimulation of the CB1 receptor may also lead to progression of liver steatosis and carcinogenesis. In end-stage liver disease, the endocannabinoid system plays an important role in the pathogenesis of encephalopathy and vascular effects, such as portal hypertension, splanchnic vasodilatation and cirrhotic cardiomyopathy. It seems that interference in endocannabinoid transmission may serve as an attractive target for the development of hepatological drugs.
keywords:

liver diseases, cannabinoids, CB1, CB2, endocannabinoids

Quick links
© 2025 Termedia Sp. z o.o.
Developed by Bentus.